TransMedics Group, Inc. (TMDX) News
Filter TMDX News Items
TMDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TMDX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TMDX News From Around the Web
Below are the latest news stories about TRANSMEDICS GROUP INC that investors may wish to consider to help them evaluate TMDX as an investment opportunity.
Scorpion Capital shorts TransMedics, alleging fraud in reportShares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The investment firm alleges fraudulent practices at TransMedics, describing it as "the most extreme and grotesque healthcare fraud we have encountered." Market Domination hosts Julie Hyman and Josh Lipton examine the details behind these allegations. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith |
Why TransMedics Group Stock Is Tanking TodayShares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics. Scorpion stated in its report, "TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients -- the terminally ill, desperate for an organ." |
TransMedics Shares Plunge Following Short Seller AllegationsScorpion Capital's report accuses TransMedics of unethical practices |
Scorpion Capital shorts TransMedics, shares downInvesting.com -- Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, and unreported device failures. |
2 MedTech Stocks That Are Screaming Buys in JanuaryAt the intersection of healthcare and technology, medtech companies are leveraging innovative solutions to improve patient care and health outcomes. Industry leaders are well-positioned to deliver shareholder value by addressing the growing healthcare demands of an aging global population and the rising prevalence of chronic diseases. Recent breakthroughs in artificial intelligence (AI) and robotics have unlocked new growth opportunities, further supporting a robust long-term outlook. |
Should We Be Delighted With TransMedics Group, Inc.'s (NASDAQ:TMDX) ROE Of 16%?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
Why Transmedics Plunged in DecemberShares of Transmedics (NASDAQ: TMDX) fell 28.1% in December, according to data from S&P Global Market Intelligence. On Dec. 2, Transmedics announced it had appointed Gerardo Hernandez as CFO, replacing current CFO Stephen Gordon effective immediately. Gordon will stay on in a nonexecutive role until March 2025, then act as an advisor to the company through March 2026. |
1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025As substantial as TransMedics' stock sell-off has been, its underlying business is by no means 63% worse. As we keep our gaze upon a decades-long time frame rather than mere days, here is why I believe TransMedics looks like a super growth stock to consider in 2025 while its stock remains discounted. Simply put, TransMedics' Organ Care System (OCS) delivers vastly superior transplant outcomes than the traditional ice storage process used historically in organ donations. |
TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceTransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 2:15 p.m. Pacific Standard Time / 5:15 p.m. Eastern Standard Time. |
TransMedics Stock Plunges 57.5% in Three Months: What's Next?TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance. |